| 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol |
292 |
| 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society |
256 |
| 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary |
194 |
| Myocarditis in Patients Treated With Immune Checkpoint Inhibitors |
156 |
| 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease |
145 |
| 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary |
140 |
| Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation Expert Recommendations |
137 |
| Air Pollution and Cardiovascular Disease JACC State-of-the-Art Review |
120 |
| 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/N MA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines |
110 |
| Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury JACC Review Topic of the Week |
96 |
| Inflammation, Immunity, and Infection in Atherothrombosis JACC Review Topic of the Week |
89 |
| Coronary Calcium Score and Cardiovascular Risk |
79 |
| Artificial Intelligence in Cardiology |
79 |
| Promoting Physical Activity and Exercise JACC Health Promotion Series |
77 |
| Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics |
76 |
| Transthyretin Amyloid Cardiomyopathy JACC State-of-the-Art Review |
76 |
| Genomic Risk Prediction of Coronary Artery Disease in 000 Adults Implications for Primary Prevention |
76 |
| Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study |
73 |
| Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk |
73 |
| Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1 beta/NLRP3 Inflammasome |
71 |
| 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/N MA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines |
69 |
| Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study |
68 |
| 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease |
68 |
| 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease |
67 |
| 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients |
66 |
| Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina The CorMicA Trial |
65 |
| Healthy Weight and Obesity Prevention JACC Health Promotion Series |
64 |
| Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction |
62 |
| Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation The ULTIMATE Trial |
62 |
| Mortality Not Correlated With Paclitaxel Exposure An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon |
59 |
| Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity |
59 |
| Stress Cardiomyopathy Diagnosis and Treatment JACC State-of-the-Art Review |
59 |
| Endothelial to Mesenchymal Transition in Cardiovascular Disease JACC State-of-the-Art Review |
58 |
| Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT |
58 |
| Myocardial Interstitial Fibrosis in Heart Failure Biological and Translational Perspectives |
57 |
| Long-Term Durability of Transcatheter Aortic Valve Prostheses |
56 |
| Cryptogenic Stroke and High-Risk Patent Foramen Ovale The DEFENSE-PFO Trial |
55 |
| Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium |
55 |
| 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary |
55 |
| Clinical Genetic Testing for Familial Hypercholesterolemia |
54 |
| Large-Artery Stiffness in Health and Disease JACC State-of-the-Art Review |
53 |
| Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction |
53 |
| Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline |
53 |
| Intestinal Microbiota in Cardiovascular Health and Disease |
52 |
| Sitting Time, Physical Activity, and Risk of Mortality in Adults |
52 |
| Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options JACC State-of-the-Art Review |
51 |
| Standardized Team-Based Care for Cardiogenic Shock |
51 |
| Left Atrial Structure and Function, and Left Ventricular Diastolic Dysfunction JACC State-of-the-Art Review |
50 |
| Pregnancy Outcomes in Women With Heart Disease The CARPREG II Study |
50 |
| ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison |
49 |
| Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation |
48 |
| Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock |
48 |
| 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways |
47 |
| Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes |
47 |
| Artificial Intelligence in Cardiovascular Imaging JACC State-of-the-Art Review |
47 |
| Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction |
47 |
| 1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification |
46 |
| Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) |
46 |
| Transcatheter Tricuspid Valve Interventions Landscape, Challenges, and Future Directions |
45 |
| Chronic Kidney Disease and Coronary Artery Disease |
44 |
| NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis |
44 |
| Smartwatch Algorithm for Automated Detection of Atrial Fibrillation |
44 |
| Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis |
44 |
| Prosthesis-Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement From the STS/ACC TVT Registry |
44 |
| Angiotensin-Converting Enzyme Inhibitors in Hypertension To Use or Not to Use? |
44 |
| Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit |
44 |
| Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting |
44 |
| Obesity Pathophysiology and Management |
43 |
| Coronary Angiography and Percutaneous Coronary Intervention After Transcatheter Aortic Valve Replacement |
43 |
| Present Status of Brugada Syndrome JACC State-of-the-Art Review |
43 |
| The Role of Nutraceuticals in Statin Intolerant Patients |
42 |
| Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation |
42 |
| Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock |
42 |
| Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs |
42 |
| Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction |
42 |
| Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis |
42 |
| Vascular Cognitive Impairment and Dementia |
42 |
| His Bundle Pacing |
41 |
| Environmental Noise and the Cardiovascular System |
41 |
| Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation |
40 |
| Long-Term Prognosis of Patients With Takotsubo Syndrome |
40 |
| Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation |
39 |
| Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer |
39 |
| PCI and CABG for Treating Stable Coronary Artery Disease JACC Review Topic of the Week |
39 |
| Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk |
39 |
| Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis |
39 |
| Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management |
38 |
| Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance (Retracted article. See vol. pg. 2020) |
38 |
| Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke |
38 |
| 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary |
37 |
| Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial |
37 |
| Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes The FREEDOM Follow-On Study |
37 |
| Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert Panel |
37 |
| Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring |
37 |
| Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes |
37 |
| Thyroid Hormones and Cardiovascular Function and Diseases |
37 |
| Anatomy, Function, and Dysfunction of the Right Ventricle JACC State-of-the-Art Review |
37 |
| Venoarterial ECMO for Adults JACC Scientific Expert Panel |
36 |
| Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy |
36 |
| Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy |
36 |
| Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia |
35 |
| Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes |
35 |
| Supplemental Vitamins and Minerals for CVD Prevention and Treatment |
35 |
| Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation |
35 |
| Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation The COAPT Trial |
35 |
| Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction |
35 |
| Management of Conduction Disturbances Associated With Transcatheter Aortic Valve Replacement JACC Scientific Expert Panel |
35 |
| 6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation |
34 |
| Exercise Intolerance in Patients With Heart Failure |
34 |
| Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy |
34 |
| 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials |
33 |
| Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes |
33 |
| Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial |
33 |
| Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis |
33 |
| Nonalcoholic Fatty Liver Disease and the Heart JACC State-of-the-Art Review |
32 |
| Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes The PHARMCLO Trial |
32 |
| Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF |
31 |
| 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay |
31 |
| Positive Psychological Well-Being and Cardiovascular Disease JACC Health Promotion Series |
31 |
| Impact of Lipids on Cardiovascular Health JACC Health Promotion Series |
31 |
| Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI JACC State-of-the-Art Review |
31 |
| Prevention of Arrhythmia Device Infection Trial The PADIT Trial |
31 |
| Cardiorespiratory Fitness and Mortality in Healthy Men and Women |
31 |
| Type 2 Myocardial Infarction JACC Review Topic of the Week |
31 |
| Outcomes of Donation After Circulatory Death Heart Transplantation in Australia |
31 |
| Coronary Artery Disease and Transcatheter Aortic Valve Replacement JACC State-of-the-Art Review |
30 |
| 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents |
30 |
| His Resynchronization Versus Biventricular Pacing in Patients With Heart Failure and Left Bundle Branch Block |
30 |
| Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy |
30 |
| Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI |
30 |
| Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity |
30 |
| 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary |
30 |
| From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events JACC State-of-the-Art Review |
29 |
| Clinical Outcomes of Infective Endocarditis in Injection Drug Users |
29 |
| Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women |
29 |
| Multimorbidity in Older Adults With Cardiovascular Disease |
29 |
| Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction COMPLETE Trial |
29 |
| B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan The PARADIGM-HF Trial |
29 |
| Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction |
29 |
| Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia JACC State-of-the-Art Review |
29 |
| Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy |
28 |
| 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor |
28 |
| Atrial Fibrillation and Cognitive Function JACC Review Topic of the Week |
28 |
| Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation |
28 |
| F-18-Sodium Fluoride Uptake in Abdominal Aortic Aneurysms The SoFIA(3) Study |
28 |
| Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve |
28 |
| 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses |
28 |
| The Macrophage in Cardiac Homeostasis and Disease JACC Macrophage in CVD Series (Part 4) |
28 |
| Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis JACC Macrophage in CVD Series (Part 2) |
28 |
| Myocardial Edema and Prognosis in Amyloidosis |
28 |
| Arrhythmia-Induced Cardiomyopathy JACC State-of-the-Art Review |
28 |
| ACC/AHA Versus ESC/ESH on Hypertension Guidelines |
28 |
| Primary Prevention With Statins in the Elderly |
27 |
| ACC/AHA Versus ESC Guidelines on Heart Failure JACC Guideline Comparison |
27 |
| Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women |
27 |
| Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction |
27 |
| Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events |
27 |
| Clinical Outcomes in Adolescents and Adults After the Fontan Procedure |
27 |
| Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients |
27 |
| Atrial Functional Mitral Regurgitation JACC Review Topic of the Week |
27 |
| Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation |
27 |
| Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain |
27 |
| The Long Noncoding RNA CAREL Controls Cardiac Regeneration |
27 |
| Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release |
27 |
| 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation |
26 |
| Outcome of Applying the ESC O/1-hour Algorithm in Patients With Suspected Myocardial Infarction |
26 |
| Initial Feasibility Study of a New Transcatheter Mitral Prosthesis The First 100 Patients |
26 |
| Implementation of Transcatheter Aortic Valve Replacement in France |
26 |
| Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis |
26 |
| Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses The STS/ACC Registry |
26 |
| Cardiovascular Toxicities Associated With Ibrutinib |
26 |
| Modeling Cardiovascular Risks of E-Cigarettes With Human-Induced Pluripotent Stem Cell-Derived Endothelial Cells |
26 |
| Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function |
26 |
| Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer |
26 |
| Coronary Physiology Beyond Coronary Flow Reserve in Microvascular Angina JACC State-of-the-Art Review |
25 |
| Macrophage Biology, Classification, and Phenotype in Cardiovascular Disease JACC Macrophage in CVD Series (Part 1) |
25 |
| Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial |
25 |
| 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Aortic Valve Replacement |
25 |
| SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL |
25 |
| Early Experience With New Transcatheter Mitral Valve Replacement |
25 |
| Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I |
25 |
| Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk JACC Review Topic of the Week |
25 |
| Clonal Hematopoiesis Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week |
25 |
| Sustained Physical Activity, Not Weight Loss, Associated With Improved Survival in Coronary Heart Disease |
25 |
| Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy JACC Review Topic of the Week |
25 |
| Poor Long-Term Survival in Patients With Moderate Aortic Stenosis |
25 |
| Association of Sleep Duration and Quality With Subclinical Atherosclerosis |
24 |
| Digoxin and Mortality in Patients With Atrial Fibrillation |
24 |
| External Validation of the DAPT Score in a Nationwide Population |
24 |
| Orthostatic Hypotension JACC State-of-the-Art Review |
24 |
| Anterior Leaflet Laceration to Prevent Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Replacement |
24 |
| Targeting the Immune System in Atherosclerosis |
24 |
| The Mitral Annulus Disjunction Arrhythmic Syndrome |
24 |
| Guiding Therapy by Coronary CT Angiography Improves Outcomes in Patients With Stable Chest Pain |
24 |
| Association of Assisted Reproductive Technologies With Arterial Hypertension During Adolescence |
24 |
| Cardiac Calcitropes, Myotropes, and Mitotropes JACC Review Topic of the Week |
24 |
| Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting |
24 |
| Myocardial Fibrosis in Patients With Primary Mitral Regurgitation With and Without Prolapse |
24 |
| Rapid Deployment Versus Conventional Bioprosthetic Valve Replacement for Aortic Stenosis |
23 |
| Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis The TOPAS-TAVI Registry |
23 |
